IndiviorINDV
INDV
About: Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Employees: 1,164
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
554% more call options, than puts
Call options by funds: $962K | Put options by funds: $147K
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
11.28% more ownership
Funds ownership: 61.94% [Q4 2024] → 73.22% (+11.28%) [Q1 2025]
3% more funds holding
Funds holding: 111 [Q4 2024] → 114 (+3) [Q1 2025]
11% less capital invested
Capital invested by funds: $974M [Q4 2024] → $866M (-$108M) [Q1 2025]
18% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 40
50% less funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 4 (-4) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$22
42%
upside
Avg. target
$22
42%
upside
High target
$22
42%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Chase Knickerbocker | 42%upside $22 | Buy Maintained | 30 Jun 2025 |
Financial journalist opinion
Based on 5 articles about INDV published over the past 30 days
Neutral
PRNewsWire
3 days ago
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs
RICHMOND, Va. , July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025.
Positive
Zacks Investment Research
1 week ago
Indivior (INDV) Moves 5.7% Higher: Will This Strength Last?
Indivior (INDV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
PRNewsWire
1 week ago
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes
RICHMOND, Va., June 30, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as part of the 2025 Russell indexes reconstitution.
Neutral
PRNewsWire
2 weeks ago
Indivior Appoints Tony Kingsley to the Board of Directors
RICHMOND, Va. , June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025.
Neutral
PRNewsWire
3 weeks ago
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1 Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often affected by higher drug overdose death rates compared to other racial and ethnic groups2-5 RICHMOND, Va. , June 19, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting.
Negative
Proactive Investors
1 month ago
Indivior brings curtain down on turbulent 11-year run in London
Indivior PLC (LSE:INDV) is set to end its secondary listing on the London Stock Exchange, drawing a line under a volatile 11-year chapter as a UK-listed company following its spin-out from Reckitt Benckiser in 2014. Its tenure as a London-listed company was marred by legal battles over its opioid treatments, loss of patent protection, investor distrust, and a growing disconnect between its UK listing and US-focused operations.
Neutral
Reuters
1 month ago
Indivior to delist from London Stock Exchange, maintain Nasdaq listing
Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align with its U.S.-centric business.
Neutral
PRNewsWire
1 month ago
Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
SLOUGH, England and RICHMOND, Va. , June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("Ordinary Shares") on the Equity Shares (Transition) category of the Official List (the "Official List") of the U.K. Financial Conduct Authority ("FCA"); and (ii) the admission to trading of its Ordinary Shares on the London Stock Exchange's ("LSE") main market for listed securities (together, the "London Delisting").
Neutral
PRNewsWire
1 month ago
Indivior Announces Patrick Barry as Chief Commercial Officer
Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va. , May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2.
Neutral
PRNewsWire
1 month ago
Indivior to Participate in Upcoming Investor Events
RICHMOND, Va. , May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New York City, NY Joe Ciaffoni, Chief Executive Officer, and Ryan Preblick, Chief Financial Officer, will host 1x1 / group meetings on Wednesday, June 4 th.
Charts implemented using Lightweight Charts™